Innovative Drugs Were Some Top 2020 Specialty Trends

January 1

While the COVID-19 pandemic and pharma’s efforts to counter it were the top pharma concerns in 2020, that wasn’t the only innovation within the specialty pharmacy arena. AIS Health spoke with a variety of industry experts on various trends over the past year.

What were some of the most notable developments within the specialty pharmacy industry in 2020, and why?

David Lassen, Pharm.D., chief clinical officer at Prime Therapeutics LLC: “There were many approvals for rare conditions that previously had limited or no treatment options. These include:

“Two new agents, Enspryng and Uplizna, to treat neuromyelitis optica spectrum disorder (NMOSD). These agents will compete with Soliris and off-label Rituxan and at a lower cost compared to Soliris.

0 Comments

Radar on Specialty Pharmacy

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Court Rulings Temporarily Block MFN Model Implementation January 1, 2021

FDA Approves First Oral Therapy For Prevention of HAE Attacks January 1, 2021

fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper

September 12

New FDA Approvals: FDA Approved Citius’ Lymphir for CTCL

September 12

Evernorth Reveals Stelara Biosimilar Strategy, but Will Others Get Same Discount?

September 12

Quantile Health Wants to Help Self-Insured Plans Access CGTs

directory-of-health-plans-test-drive-directory-of-health-plans-ad

Meet Our Reporters

Jill Drachenberg Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jill Drachenberg's Profile
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile

Innovative Drugs Were Some Top 2020 Specialty Trends

What were some of the most notable developments within the specialty pharmacy industry in 2020, and why?

Angela Maas

Related Posts

New FDA Approvals: FDA Approved Citius’ Lymphir for CTCL

Evernorth Reveals Stelara Biosimilar Strategy, but Will Others Get Same Discount?

Quantile Health Wants to Help Self-Insured Plans Access CGTs

The Latest

Premium Categories

Meet Our Reporters

Jill Drachenberg Reporter, Health Plan Weekly and Radar on Drug Benefits

Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage

Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access

Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits

Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits

Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access

Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND